BioSpace News Archive

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2022.

STAAR Surgical Company, a leading developer, manufacturer and marketer of implantable lenses for the eye, reported financial results for the fourth quarter and fiscal year ended December 30, 2022.

AtriCure, Inc., a leading innovator in surgical treatments and therapies for atrial fibrillation, left atrial appendage management and post-operative pain management, announced fourth quarter 2022 and full year 2022 financial results.

Revance Therapeutics, Inc. (RVNC), today announced that the company will release fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023, after the close of market.

Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) (“Dermata,” or the “Company”), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today highlighted recent corporate progress, and reported financial results for the year ended December 31, 2022.

Globus Medical, Inc., a leading musculoskeletal solutions company, announced its financial results for the fourth quarter and year ended December 31, 2022.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its fourth quarter and full year 2022 financial results and business highlights.

First Wave BioPharma, Inc. announced that an abstract entitled, “Results from an Open-Label, Phase 2 Study with Escalating Doses of Adrulipase Alfa on top of a Stable Dose of Porcine Pancreatic Enzymes in CF Patients Not Fully Compensated with PPE as Sole Therapy,” has been accepted for a presentation at the 2023 Digestive Disease Week Conference.

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the submission of its supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) to request approval of XHANCE as a treatment for chronic rhinosinusitis.

uniQure N.V. (NASDAQ: QURE) announced that its partner, global biotechnology leader CSL (ASX: CSL), has received conditional marketing authorization (CMA) from the European Commission for HEMGENIX® (etranacogene dezaparvovec), the first and only one-time gene therapy for the treatment of severe and moderately severe hemophilia B.